A Randomized,Double-Blind,Placebo-Controlled,Phase IIa,Parallel Group, Two-Cohort Study to Define the Safety, Tolerability,Clinical and Exploratory Biological Activity of the ChronicAdministration of Nilotinib in Participants with Parkinson's Disease